EBS
Emergent Biosolutions Inc
6.80$
+0.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.2% | 11.6% | -20.8% | 18.6% | 52.3% | -41.0% | -5.0% | 75.5% | -1.0% | 52.3% | -21.7% | 23.9% | 12.7% | |
| 10.4% | 10.7% | 9.3% | 11.2% | 9.0% | 13.4% | 11.4% | 16.7% | 10.1% | 15.8% | 15.1% | 10.2% | 12.3% | |
| 1.5% | 1.4% | 2.0% | 2.2% | 0.8% | 2.2% | 0.7% | 3.3% | 2.1% | 3.6% | 1.2% | 2.9% | 2.5% | |
| 84.2% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 24.3% | 16.8% | -32.5% | 80.8% | 22.3% | -43.8% | -53.4% | 67.9% | -35.2% | 55.1% | -33.2% | -10.5% | -9.9% | |
| 4.7% | 4.1% | 3.6% | 1.8% | 2.0% | 0.9% | 1.6% | 2.1% | 1.5% | 2.6% | 1.5% | 0.9% | 1.5% | |
| -7.0% | -4.1% | -3.6% | -1.8% | 38.1% | 14.7% | 26.8% | 12.2% | -1.5% | -2.6% | -1.5% | -22.3% | -8.0% | |
| 0.7% | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | -0.1% | -0.1% | 0.2% | 12.4% | 0.0% | -4.9% | -3.9% | -6.1% | -5.8% | -3.8% | -4.7% | |
| -15.9% | – | – | – | -66.0% | 0.0% | 0.0% | 0.0% | -3.0% | -68.5% | – | – | – | |
| -15.9% | 1.7% | 13.5% | -20.0% | -61.4% | 0.3% | -0.2% | -4.5% | -6.9% | -76.6% | -7.3% | -10.4% | -21.5% | |
| -0.3% | 8.6% | -10.9% | -3.1% | 29.1% | -26.1% | 21.2% | 83.9% | -9.4% | -27.0% | -30.5% | -8.8% | -16.9% | |
| 17.5% | 7.5% | -24.4% | 16.8% | 50.3% | -41.9% | -6.7% | 73.5% | -2.5% | 49.6% | -23.2% | 23.0% | 11.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.